Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence / Krasniqi, Eriseld; Pizzuti, Laura; Barchiesi, Giacomo; Sergi, Domenico; Carpano, Silvia; Botti, Claudio; Kayal, Ramy; Sanguineti, Giuseppe; Marchetti, Paolo; Botticelli, Andrea; Marinelli, Daniele; Gamucci, Teresa; Natoli, Clara; Grassadonia, Antonino; Tinari, Nicola; Tomao, Silverio; Tonini, Giuseppe; Santini, Daniele; Michelotti, Aandrea; Mentuccia, Lucia; Vaccaro, Aangela; Magnolfi, Emanuela; Gelibter, Alain Jonathan; Magri, Valentina; Cortesi, Enrico; D'Onofrio, Loretta; Cassano, Alessandra; Cazzaniga, Marina; Moscetti, Luca; Fabbri, Agnese; Fedele Scinto, Angelo; Corsi, Domenico; Carbognin, Luisa; Bria, Emilio; La Verde, Nicla; Garufi, Carlo; Di Stefano, Pia; Mirabelli, Rossana; Veltri, Enzo; Paris, Ida; Giotta, Francesco; Lorusso, Vito; Landucci, Elisa; Ficorella, Corrado; Roselli, Mario; Adamo, Vincenzo; Ricciardi, Giuseppina; Russo, Antonio; Rosaria Valerio, Maria; Berardi, Rossana; Pistelli, Mirco; Cannita, Katia; Zamagni, Claudio; Garrone, Ornella; Baldini, Editta; Livi, Lorenzo; Meattini, Icro; Del Medico, Pietro; Generali, Daniele; De Maria, Ruggero; Risi, Emanuela; Ciliberto, Gennaro; Villa, Alice; Sperduti, Isabella; Mazzotta, Marco; Barba, Maddalena; Giordano, Antonio; Vici, Patrizia. - In: JOURNAL OF CELLULAR PHYSIOLOGY. - ISSN 0021-9541. - 235:11(2020), pp. 7900-7910. [10.1002/jcp.29445]

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

Laura Pizzuti
Co-primo
;
Giacomo Barchiesi;Paolo Marchetti;Andrea Botticelli;Daniele Marinelli;Silverio Tomao;Alain Gelibter;Valentina Magri;Enrico Cortesi;SANTINI, DANIELE
2020

Abstract

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
body mass index; HER2-positive metastatic breast cancer; pertuzumab; trastuzumab emtansine
01 Pubblicazione su rivista::01a Articolo in rivista
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence / Krasniqi, Eriseld; Pizzuti, Laura; Barchiesi, Giacomo; Sergi, Domenico; Carpano, Silvia; Botti, Claudio; Kayal, Ramy; Sanguineti, Giuseppe; Marchetti, Paolo; Botticelli, Andrea; Marinelli, Daniele; Gamucci, Teresa; Natoli, Clara; Grassadonia, Antonino; Tinari, Nicola; Tomao, Silverio; Tonini, Giuseppe; Santini, Daniele; Michelotti, Aandrea; Mentuccia, Lucia; Vaccaro, Aangela; Magnolfi, Emanuela; Gelibter, Alain Jonathan; Magri, Valentina; Cortesi, Enrico; D'Onofrio, Loretta; Cassano, Alessandra; Cazzaniga, Marina; Moscetti, Luca; Fabbri, Agnese; Fedele Scinto, Angelo; Corsi, Domenico; Carbognin, Luisa; Bria, Emilio; La Verde, Nicla; Garufi, Carlo; Di Stefano, Pia; Mirabelli, Rossana; Veltri, Enzo; Paris, Ida; Giotta, Francesco; Lorusso, Vito; Landucci, Elisa; Ficorella, Corrado; Roselli, Mario; Adamo, Vincenzo; Ricciardi, Giuseppina; Russo, Antonio; Rosaria Valerio, Maria; Berardi, Rossana; Pistelli, Mirco; Cannita, Katia; Zamagni, Claudio; Garrone, Ornella; Baldini, Editta; Livi, Lorenzo; Meattini, Icro; Del Medico, Pietro; Generali, Daniele; De Maria, Ruggero; Risi, Emanuela; Ciliberto, Gennaro; Villa, Alice; Sperduti, Isabella; Mazzotta, Marco; Barba, Maddalena; Giordano, Antonio; Vici, Patrizia. - In: JOURNAL OF CELLULAR PHYSIOLOGY. - ISSN 0021-9541. - 235:11(2020), pp. 7900-7910. [10.1002/jcp.29445]
File allegati a questo prodotto
File Dimensione Formato  
Krasniqi_Impact_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.3 MB
Formato Adobe PDF
1.3 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1363903
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 11
social impact